Clinical trial NCT00153062: PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
Official title: PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Stroke
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
Collaborators: name: GlaxoSmithKline
name: Bayer
First posted: 2005-09-12
Enrollment: 20332
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of the trial is to determine if extended-release dipyridamole + aspirin \[Aggrenox, Asasa ntin\] is superior to clopidogrel \[Plavix\], and if telmisartan \[Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan\] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.


Eligibility criteria: Inclusion criteria:

Male or female subjects 55 year or older who have suffered an ischemic stroke within the past 90 days and who meet all other inclusion criteria. Include also patients of ages 50 - 54 years and/or 90 to 120 days after the qualifying stroke provided the patient has at least two of the following additional risk factors:

* Diabetes mellitus
* Hypertension (systolic BP ¿ 140 or diastolic BP ¿ 90)
* Smoker at time of qualifying stroke
* Obesity (BMI\>30; BMI=weight (kg)/\[height (m)\]2)
* Previous vascular disease (stroke, MI, or peripheral arterial disease prior to qualifying stroke)
* End-organ-damage (retinopathy, LVH, or microalbuminuria)
* Hyperlipidemia

Exclusion criteria:

hemorrhagic stroke (must be ruled out by imaging);unable to give informed consent; known brain tumor, severe renal or hepatic insufficiency, current active peptic ulcer disease, severe coronary artery disease including unstable angina pectoris or an MI within the previous 3 months,or history of a hemostatic disorder or systemic bleeding ;hyperkalemia;uncorrected volume or sodium depletion; pre-stroke history of dementia;modified Rankin score greater than 4;qualifying stroke induced by surgical or cardiovascular procedure;uncontrolled hypertension at entry above 180/110 mmHg (goal BPs are lower); SBP 120 mmHg or less for hospitalized patients; currently taking an ARB and not able or willing to switch to alternative; required or planned continuing treatment with antithrombotics or anticoagulants including heparin or warfarin or non-study platelet inhibitors; syndrome of asthma, rhinitis and nasal polyps;scheduled for major surgery, carotid endarterectomy, or carotid angioplasty (4 weeks post surgery is allowed);unlikely to be released from hospital following the qualifying stroke or presence of a severe disability likely to lead to being bedridden or demented or a non-vascular disease or condition which makes it unlikely that the patient will survive to the end of the trial; history of thrombocytopenia or neutropenia.

Primary outcomes:
measure: Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)
timeFrame: time since randomization; follow-up period is 1.5 to 4.4 years
measure: Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)
timeFrame: time since randomization; follow-up period is 1.5 to 4.4 years
Secondary outcomes:
measure: Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)
timeFrame: time since randomization; follow-up period is 1.5 to 4.4 years
measure: Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)
timeFrame: time since randomization; follow-up period is 1.5 to 4.4 years
measure: Number of Patients With New Onset of Diabetes (Telmisartan vs. Placebo Only)
timeFrame: Randomization to final patient contact
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: 9.159.1101 Boehringer Ingelheim Investigational Site
state: Alabama
city: Huntsville
country: United States
facility: 9.159.1173 Boehringer Ingelheim Investigational Site
state: Alabama
city: Mobile
country: United States
facility: 9.159.1058 Boehringer Ingelheim Investigational Site
state: Alabama
city: Montgomery
country: United States
facility: 9.159.1087 Boehringer Ingelheim Investigational Site
state: Alabama
city: Northport
country: United States
facility: 9.159.1081 Boehringer Ingelheim Investigational Site
state: Alabama
city: Phoenix
country: United States
facility: 9.159.1022 Boehringer Ingelheim Investigational Site
state: Arizona
city: Phoenix
country: United States
facility: 9.159.1133 Boehringer Ingelheim Investigational Site
state: Arizona
city: Phoenix
country: United States
facility: 9.159.1149 Boehringer Ingelheim Investigational Site
state: Arizona
city: Tucson
country: United States
facility: 9.159.1137 Boehringer Ingelheim Investigational Site
state: Arizona
city: Fayetteville
country: United States
facility: 9.159.1184 Boehringer Ingelheim Investigational Site
state: Arkansas
city: Fort Smith
country: United States
facility: 9.159.1005 Boehringer Ingelheim Investigational Site
state: Arkansas
city: Jonesboro
country: United States
facility: 9.159.1136 Boehringer Ingelheim Investigational Site
state: Arkansas
city: Little Rock
country: United States
facility: 9.159.1062 Boehringer Ingelheim Investigational Site
state: Arkansas
city: Berkeley
country: United States
facility: 9.159.1040 Boehringer Ingelheim Investigational Site
state: California
city: Carmichael
country: United States
facility: 9.159.1180 Boehringer Ingelheim Investigational Site
state: California
city: Irvine
country: United States
facility: 9.159.1114 Boehringer Ingelheim Investigational Site
state: California
city: Laguna Hills
country: United States
facility: 9.159.1202 Boehringer Ingelheim Investigational Site
state: California
city: Los Angeles
country: United States
facility: 9.159.1036 Boehringer Ingelheim Investigational Site
state: California
city: Los Angeles
country: United States
facility: 9.159.1052 Boehringer Ingelheim Investigational Site
state: California
city: Los Angeles
country: United States
facility: 9.159.1100 Boehringer Ingelheim Investigational Site
state: California
city: Los Angeles
country: United States
facility: 9.159.1111 Boehringer Ingelheim Investigational Site
state: California
city: Los Angeles
country: United States
facility: 9.159.1165 Boehringer Ingelheim Investigational Site
state: California
city: Oceanside
country: United States
facility: 9.159.1134 Boehringer Ingelheim Investigational Site
state: California
city: Palo Alto
country: United States
facility: 9.159.1002 Boehringer Ingelheim Investigational Site
state: California
city: Redding
country: United States
facility: 9.159.1108 Boehringer Ingelheim Investigational Site
state: California
city: Sacramento
country: United States
facility: 9.159.1013 Boehringer Ingelheim Investigational Site
state: California
city: Sacramento
country: United States
facility: 9.159.1198 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 9.159.1029 Boehringer Ingelheim Investigational Site
state: California
city: San Francisco
country: United States
facility: 9.159.1185 Boehringer Ingelheim Investigational Site
state: California
city: San Jose
country: United States
facility: 9.159.1218 Boehringer Ingelheim Investigational Site
state: California
city: Santa Rosa
country: United States
facility: 9.159.1179 Boehringer Ingelheim Investigational Site
state: California
city: Sylmar
country: United States
facility: 9.159.1162 Boehringer Ingelheim Investigational Site
state: California
city: Torrance
country: United States
facility: 9.159.1183 Boehringer Ingelheim Investigational Site
state: California
city: Walnut Creek
country: United States
facility: 9.159.1205 Boehringer Ingelheim Investigational Site
state: California
city: Denver
country: United States
facility: 9.159.1118 Boehringer Ingelheim Investigational Site
state: Colorado
city: Englewood
country: United States
facility: 9.159.1045 Boehringer Ingelheim Investigational Site
state: Colorado
city: Danbury
country: United States
facility: 9.159.1038 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Fairfield
country: United States
facility: 9.159.1196 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Hartford
country: United States
facility: 9.159.1018 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Newark
country: United States
facility: 9.159.1080 Boehringer Ingelheim Investigational Site
state: Delaware
city: Washington
country: United States
facility: 9.159.1120 Boehringer Ingelheim Investigational Site
state: District of Columbia
city: Washington
country: United States
facility: 9.159.1216 Boehringer Ingelheim Investigational Site
state: District of Columbia
city: Bay Pines
country: United States
facility: 9.159.1057 Boehringer Ingelheim Investigational Site
state: Florida
city: Boca Raton
country: United States
facility: 9.159.1217 Boehringer Ingelheim Investigational Site
state: Florida
city: Bradenton
country: United States
facility: 9.159.1096 Boehringer Ingelheim Investigational Site
state: Florida
city: Clearwater
country: United States
facility: 9.159.1144 Boehringer Ingelheim Investigational Site
state: Florida
city: Ft. Lauderdale
country: United States
facility: 9.159.1007 Boehringer Ingelheim Investigational Site
state: Florida
city: Jacksonville
country: United States
facility: 9.159.1190 Boehringer Ingelheim Investigational Site
state: Florida
city: Ocala
country: United States
facility: 9.159.1150 Boehringer Ingelheim Investigational Site
state: Florida
city: Panama City
country: United States
facility: 9.159.1153 Boehringer Ingelheim Investigational Site
state: Florida
city: Plantation
country: United States
facility: 9.159.1041 Boehringer Ingelheim Investigational Site
state: Florida
city: Port Charlotte
country: United States
facility: 9.159.1072 Boehringer Ingelheim Investigational Site
state: Florida
city: Sarasota
country: United States
facility: 9.159.1063 Boehringer Ingelheim Investigational Site
state: Florida
city: Tampa
country: United States
facility: 9.159.1208 Boehringer Ingelheim Investigational Site
state: Florida
city: Vero Beach
country: United States
facility: 9.159.1049 Boehringer Ingelheim Investigational Site
state: Florida
city: West Palm Beach
country: United States
facility: 9.159.1176 Boehringer Ingelheim Investigational Site
state: Florida
city: Atlanta
country: United States
facility: 9.159.1071 Boehringer Ingelheim Investigational Site
state: Georgia
city: Augusta
country: United States
facility: 9.159.1079 Boehringer Ingelheim Investigational Site
state: Georgia
city: Columbus
country: United States
facility: 9.159.1181 Boehringer Ingelheim Investigational Site
state: Georgia
city: Decatur
country: United States
facility: 9.159.1138 Boehringer Ingelheim Investigational Site
state: Georgia
city: Rome
country: United States
facility: 9.159.1070 Boehringer Ingelheim Investigational Site
state: Georgia
city: Savannah
country: United States
facility: 9.159.1107 Boehringer Ingelheim Investigational Site
state: Georgia
city: Boise
country: United States
facility: 9.159.1189 Boehringer Ingelheim Investigational Site
state: Idaho
city: Chicago
country: United States
facility: 9.159.1026 University of Illinois
state: Illinois
city: Chicago
country: United States
facility: 9.159.1033 Boehringer Ingelheim Investigational Site
state: Illinois
city: Chicago
country: United States
facility: 9.159.1060 Boehringer Ingelheim Investigational Site
state: Illinois
city: Maywood
country: United States
facility: 9.159.1044 Boehringer Ingelheim Investigational Site
state: Illinois
city: Palos Heights
country: United States
facility: 9.159.1054 Boehringer Ingelheim Investigational Site
state: Illinois
city: Park Ridge
country: United States
facility: 9.159.1068 Boehringer Ingelheim Investigational Site
state: Illinois
city: Peoria
country: United States
facility: 9.159.1178 Boehringer Ingelheim Investigational Site
state: Illinois
city: Elkhart
country: United States
facility: 9.159.1156 Boehringer Ingelheim Investigational Site
state: Indiana
city: South Bend
country: United States
facility: 9.159.1092 Boehringer Ingelheim Investigational Site
state: Indiana
city: Cedar Rapids
country: United States
facility: 9.159.1027 Boehringer Ingelheim Investigational Site
state: Iowa
city: Des Moines
country: United States
facility: 9.159.1119 Boehringer Ingelheim Investigational Site
state: Iowa
city: Des Moines
country: United States
facility: 9.159.1187 Boehringer Ingelheim Investigational Site
state: Iowa
city: Iowa City
country: United States
facility: 9.159.1059 Boehringer Ingelheim Investigational Site
state: Iowa
city: Waterloo
country: United States
facility: 9.159.1135 Boehringer Ingelheim Investigational Site
state: Iowa
city: Kansas City
country: United States
facility: 9.159.1090 Boehringer Ingelheim Investigational Site
state: Kansas
city: Lexington
country: United States
facility: 9.159.1129 Central Baptis Hospital
state: Kentucky
city: Lexington
country: United States
facility: 9.159.1131 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Lexington
country: United States
facility: 9.159.1206 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Lexington
country: United States
facility: 9.159.1212 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Louisville
country: United States
facility: 9.159.1091 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Louisville
country: United States
facility: 9.159.1147 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Baton Rouge
country: United States
facility: 9.159.1106 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Marrero
country: United States
facility: 9.159.1194 Boehringer Ingelheim Investigational Site
state: Louisiana
city: New Orleans
country: United States
facility: 9.159.1083 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Shreveport
country: United States
facility: 9.159.1195 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Baltimore
country: United States
facility: 9.159.1024 Boehringer Ingelheim Investigational Site
state: Maryland
city: Baltimore
country: United States
facility: 9.159.1055 Boehringer Ingelheim Investigational Site
state: Maryland
city: Baltimore
country: United States
facility: 9.159.1139 Boehringer Ingelheim Investigational Site
state: Maryland
city: Boston
country: United States
facility: 9.159.1031 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Boston
country: United States
facility: 9.159.1066 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Boston
country: United States
facility: 9.159.1104 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Boston
country: United States
facility: 9.159.1166 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: South Weymouth
country: United States
facility: 9.159.1192 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Worchester
country: United States
facility: 9.159.1039 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Detroit
country: United States
facility: 9.159.1019 Boehringer Ingelheim Investigational Site
state: Michigan
city: Detroit
country: United States
facility: 9.159.1048 Boehringer Ingelheim Investigational Site
state: Michigan
city: Detroit
country: United States
facility: 9.159.1089 Boehringer Ingelheim Investigational Site
state: Michigan
city: East Lansing
country: United States
facility: 9.159.1078 Boehringer Ingelheim Investigational Site
state: Michigan
city: Grand Rapids
country: United States
facility: 9.159.1143 Boehringer Ingelheim Investigational Site
state: Michigan
city: Kalamazoo
country: United States
facility: 9.159.1102 Boehringer Ingelheim Investigational Site
state: Michigan
city: Saginaw
country: United States
facility: 9.159.1011 Boehringer Ingelheim Investigational Site
state: Michigan
city: Southfield
country: United States
facility: 9.159.1132 Boehringer Ingelheim Investigational Site
state: Michigan
city: Duluth
country: United States
facility: 9.159.1088 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Duluth
country: United States
facility: 9.159.1158 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Golden Valley
country: United States
facility: 9.159.1084 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Minneapolis
country: United States
facility: 9.159.1097 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Minneapolis
country: United States
facility: 9.159.1113 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Kansas City
country: United States
facility: 9.159.1128 St. Luke's Hospital MABSI Research
state: Missouri
city: Lees Summit
country: United States
facility: 9.159.1172 Boehringer Ingelheim Investigational Site
state: Missouri
city: Saint Louis
country: United States
facility: 9.159.1174 Boehringer Ingelheim Investigational Site
state: Missouri
city: Springfield
country: United States
facility: 9.159.1009 Boehringer Ingelheim Investigational Site
state: Missouri
city: St. Louis
country: United States
facility: 9.159.1182 Boehringer Ingelheim Investigational Site
state: Missouri
city: St. Louis
country: United States
facility: 9.159.1191 Boehringer Ingelheim Investigational Site
state: Missouri
city: Great Falls
country: United States
facility: 9.159.1146 Boehringer Ingelheim Investigational Site
state: Montana
city: Omaha
country: United States
facility: 9.159.1201 Boehringer Ingelheim Investigational Site
state: Nebraska
city: Las Vegas
country: United States
facility: 9.159.1127 Boehringer Ingelheim Investigational Site
state: Nevada
city: Reno
country: United States
facility: 9.159.1188 Boehringer Ingelheim Investigational Site
state: Nevada
city: Camden
country: United States
facility: 9.159.1204 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Edison
country: United States
facility: 9.159.1203 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Lumberton
country: United States
facility: 9.159.1042 Neurology Consultants of Burlington County
state: New Jersey
city: New Brunswick
country: United States
facility: 9.159.1209 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Newark
country: United States
facility: 9.159.1125 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Ridgewood
country: United States
facility: 9.159.1095 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Albuquerque
country: United States
facility: 9.159.1170 Boehringer Ingelheim Investigational Site
state: New Mexico
city: Albany
country: United States
facility: 9.159.1086 Boehringer Ingelheim Investigational Site
state: New York
city: Bronx
country: United States
facility: 9.159.1121 Boehringer Ingelheim Investigational Site
state: New York
city: Bronx
country: United States
facility: 9.159.1130 Boehringer Ingelheim Investigational Site
state: New York
city: Brooklyn
country: United States
facility: 9.159.1017 Boehringer Ingelheim Investigational Site
state: New York
city: Brooklyn
country: United States
facility: 9.159.1064 Boehringer Ingelheim Investigational Site
state: New York
city: Brooklyn
country: United States
facility: 9.159.1186 Boehringer Ingelheim Investigational Site
state: New York
city: Buffalo
country: United States
facility: 9.159.1151 Boehringer Ingelheim Investigational Site
state: New York
city: Manasset
country: United States
facility: 9.159.1076 North Shore University Hospital
state: New York
city: Mineola
country: United States
facility: 9.159.1037 Boehringer Ingelheim Investigational Site
state: New York
city: New Hyde Park
country: United States
facility: 9.159.1220 Boehringer Ingelheim Investigational Site
state: New York
city: New York
country: United States
facility: 9.159.1001 Boehringer Ingelheim Investigational Site
state: New York
city: New York
country: United States
facility: 9.159.1116 Boehringer Ingelheim Investigational Site
state: New York
city: New York
country: United States
facility: 9.159.1142 Saint Luke's-Roosevelt Hospital
state: New York
city: Schenectady
country: United States
facility: 9.159.1126 Boehringer Ingelheim Investigational Site
state: New York
city: Stony Brook
country: United States
facility: 9.159.1163 Boehringer Ingelheim Investigational Site
state: New York
city: Tonawanda
country: United States
facility: 9.159.1169 Boehringer Ingelheim Investigational Site
state: New York
city: White Plains
country: United States
facility: 9.159.1065 Boehringer Ingelheim Investigational Site
state: New York
city: Asheville
country: United States
facility: 9.159.1099 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Chapel Hill
country: United States
facility: 9.159.1046 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Durham
country: United States
facility: 9.159.1094 Boehringer Ingelheim Investigational Site
state: North Carolina
city: High Point
country: United States
facility: 9.159.1012 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Wilmington
country: United States
facility: 9.159.1115
state: North Carolina
city: Winston-Salem
country: United States
facility: 9.159.1051 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Winston-Salem
country: United States
facility: 9.159.1110 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Bismarck
country: United States
facility: 9.159.1215 Boehringer Ingelheim Investigational Site
state: North Dakota
city: Fargo
country: United States
facility: 9.159.1152 Boehringer Ingelheim Investigational Site
state: North Dakota
city: Akron
country: United States
facility: 9.159.1159 Boehringer Ingelheim Investigational Site
state: Ohio
city: Canton
country: United States
facility: 9.159.1085 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cincinnati
country: United States
facility: 9.159.1032 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cleveland
country: United States
facility: 9.159.1025 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cleveland
country: United States
facility: 9.159.1177 Boehringer Ingelheim Investigational Site
state: Ohio
city: Columbus
country: United States
facility: 9.159.1008 Boehringer Ingelheim Investigational Site
state: Ohio
city: Columbus
country: United States
facility: 9.159.1141 Boehringer Ingelheim Investigational Site
state: Ohio
city: Toledo
country: United States
facility: 9.159.1053 Boehringer Ingelheim Investigational Site
state: Ohio
city: Youngstown
country: United States
facility: 9.159.1122 Boehringer Ingelheim Investigational Site
state: Ohio
city: Oklahoma City
country: United States
facility: 9.159.1199 Boehringer Ingelheim Investigational Site
state: Oklahoma
city: Portland
country: United States
facility: 9.159.1010 Boehringer Ingelheim Investigational Site
state: Oregon
city: Abington
country: United States
facility: 9.159.1171 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Allentown
country: United States
facility: 9.159.1210 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Allentown
country: United States
facility: 9.159.1214 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Erie
country: United States
facility: 9.159.1200 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Greensburg
country: United States
facility: 9.159.1043 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Hershey
country: United States
facility: 9.159.1164 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Lancaster
country: United States
facility: 9.159.1175 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Philadelphia
country: United States
facility: 9.159.1016 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Philadelphia
country: United States
facility: 9.159.1056 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Philadelphia
country: United States
facility: 9.159.1074 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Pittsburgh
country: United States
facility: 9.159.1112 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Upland
country: United States
facility: 9.159.1148 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Providence
country: United States
facility: 9.159.1123 Boehringer Ingelheim Investigational Site
state: Rhode Island
city: Columbia
country: United States
facility: 9.159.1140 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Greenville
country: United States
facility: 9.159.1207 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Spartanberg
country: United States
facility: 9.159.1004 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Bristol
country: United States
facility: 9.159.1006 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Knoxville
country: United States
facility: 9.159.1154 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Memphis
country: United States
facility: 9.159.1213 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Nashville
country: United States
facility: 9.159.1075 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Brownwood
country: United States
facility: 9.159.1219 Boehringer Ingelheim Investigational Site
state: Texas
city: Dallas
country: United States
facility: 9.159.1155 Boehringer Ingelheim Investigational Site
state: Texas
city: Dallas
country: United States
facility: 9.159.1197 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 9.159.1020 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 9.159.1023 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 9.159.1082 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 9.159.1160 Boehringer Ingelheim Investigational Site
state: Texas
city: San Antonio
country: United States
facility: 9.159.1047 Boehringer Ingelheim Investigational Site
state: Texas
city: Tyler
country: United States
facility: 9.159.1069 Boehringer Ingelheim Investigational Site
state: Texas
city: Bountiful
country: United States
facility: 9.159.1003 Boehringer Ingelheim Investigational Site
state: Utah
city: Newport News
country: United States
facility: 9.159.1077 Boehringer Ingelheim Investigational Site
state: Virginia
city: Richmond
country: United States
facility: 9.159.1021 Boehringer Ingelheim Investigational Site
state: Virginia
city: Salem
country: United States
facility: 9.159.1061 Boehringer Ingelheim Investigational Site
state: Virginia
city: Seattle
country: United States
facility: 9.159.1014 Boehringer Ingelheim Investigational Site
state: Washington
city: Spokane
country: United States
facility: 9.159.1145 Boehringer Ingelheim Investigational Site
state: Washington
city: Charleston
country: United States
facility: 9.159.1211 Boehringer Ingelheim Investigational Site
state: West Virginia
city: Morgantown
country: United States
facility: 9.159.1035 Boehringer Ingelheim Investigational Site
state: West Virginia
city: Marshfield
country: United States
facility: 9.159.1030 Boehringer Ingelheim Investigational Site
state: Wisconsin
city: Milwaukee
country: United States
facility: 9.159.1117 Boehringer Ingelheim Investigational Site
state: Wisconsin
city: Wausau
country: United States
facility: 9.159.1098 Community Healthcare Clinic Westhill Medical Specialists
state: Wisconsin
city: Capital Federal
country: Argentina
facility: 9.159.1331 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 9.159.1333 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 9.159.1334 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 9.159.1335 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 9.159.1336 Boehringer Ingelheim Investigational Site
city: Rosario, Sta. Fe
country: Argentina
facility: 9.159.1332 Boehringer Ingelheim Investigational Site
city: Santa Fe
country: Argentina
facility: 9.159.1342 Boehringer Ingelheim Investigational Site
city: Gosford
country: Australia
facility: 9.159.2444 Boehringer Ingelheim Investigational Site
state: New South Wales
city: New Lambton
country: Australia
facility: 9.159.2449 Boehringer Ingelheim Investigational Site
state: New South Wales
city: Westmead
country: Australia
facility: 9.159.2448 Boehringer Ingelheim Investigational Site
state: New South Wales
city: Herston
country: Australia
facility: 9.159.2450 Boehringer Ingelheim Investigational Site
state: Queensland
city: Southport
country: Australia
facility: 9.159.2452 Boehringer Ingelheim Investigational Site
state: Queensland
city: Bedford Park
country: Australia
facility: 9.159.2451 Boehringer Ingelheim Investigational Site
state: South Australia
city: Box Hill
country: Australia
facility: 9.159.2443 Boehringer Ingelheim Investigational Site
state: Victoria
city: Melbourne
country: Australia
facility: 9.159.2447 Boehringer Ingelheim Investigational Site
state: Victoria
city: Parkville
country: Australia
facility: 9.159.2445 Boehringer Ingelheim Investigational Site
state: Victoria
city: West Heidelberg
country: Australia
facility: 9.159.2446 Boehringer Ingelheim Investigational Site
state: Victoria
city: Graz
country: Austria
facility: 9.159.1515 Boehringer Ingelheim Investigational Site
city: Graz
country: Austria
facility: 9.159.1519 Boehringer Ingelheim Investigational Site
city: Innsbruck
country: Austria
facility: 9.159.1517 Boehringer Ingelheim Investigational Site
city: Linz
country: Austria
facility: 9.159.1516 Boehringer Ingelheim Investigational Site
city: Ma.Gugging/Klosterneuburg
country: Austria
facility: 9.159.1518 Boehringer Ingelheim Investigational Site
city: St. Pölten
country: Austria
facility: 9.159.1520 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 9.159.1521 Boehringer Ingelheim Investigational Site
city: Aalst
country: Belgium
facility: 9.159.1553 Boehringer Ingelheim Investigational Site
city: Anderlecht
country: Belgium
facility: 9.159.1543 Boehringer Ingelheim Investigational Site
city: Antwerpen
country: Belgium
facility: 9.159.1552 Boehringer Ingelheim Investigational Site
city: Bonheiden
country: Belgium
facility: 9.159.1546 Boehringer Ingelheim Investigational Site
city: Brugge
country: Belgium
facility: 9.159.1547 Boehringer Ingelheim Investigational Site
city: Bruxelles
country: Belgium
facility: 9.159.1550 Boehringer Ingelheim Investigational Site
city: Hasselt
country: Belgium
facility: 9.159.1549 Boehringer Ingelheim Investigational Site
city: Kortrijk
country: Belgium
facility: 9.159.1555 Boehringer Ingelheim Investigational Site
city: La Louvière
country: Belgium
facility: 9.159.1554 Boehringer Ingelheim Investigational Site
city: Leuven
country: Belgium
facility: 9.159.1544 Boehringer Ingelheim Investigational Site
city: Montegnée
country: Belgium
facility: 9.159.1548 Boehringer Ingelheim Investigational Site
city: Ottignies
country: Belgium
facility: 9.159.1556 Boehringer Ingelheim Investigational Site
city: Wilrijk
country: Belgium
facility: 9.159.1545 Boehringer Ingelheim Investigational Site
city: Yvoir
country: Belgium
facility: 9.159.1551 Boehringer Ingelheim Investigational Site
city: Salvador
country: Brazil
facility: 9.159.2869 Complexo Hospitalar Universitario Prof Edgard Santos
city: São Paulo
country: Brazil
facility: 9.159.2853 Boehringer Ingelheim Investigational Site
city: Calgary
country: Canada
facility: 9.159.1397 Foothills Medical Centre
state: Alberta
city: Edmonton
country: Canada
facility: 9.159.1382 Boehringer Ingelheim Investigational Site
state: Alberta
city: Lethbridge
country: Canada
facility: 9.159.1390 Boehringer Ingelheim Investigational Site
state: Alberta
city: Kamloops
country: Canada
facility: 9.159.1370 Boehringer Ingelheim Investigational Site
state: British Columbia
city: New Westminster
country: Canada
facility: 9.159.1368 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Penticton
country: Canada
facility: 9.159.1376 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Vancouver
country: Canada
facility: 9.159.1387 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Victoria
country: Canada
facility: 9.159.1377 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Winnipeg
country: Canada
facility: 9.159.1355 Boehringer Ingelheim Investigational Site
state: Manitoba
city: Winnipeg
country: Canada
facility: 9.159.1394 Boehringer Ingelheim Investigational Site
state: Manitoba
city: Saint John
country: Canada
facility: 9.159.1356 Boehringer Ingelheim Investigational Site
state: New Brunswick
city: Corner Brook
country: Canada
facility: 9.159.1392 Boehringer Ingelheim Investigational Site
state: Newfoundland and Labrador
city: St. John's
country: Canada
facility: 9.159.1385 Boehringer Ingelheim Investigational Site
state: Newfoundland and Labrador
city: Sydney
country: Canada
facility: 9.159.1373 Boehringer Ingelheim Investigational Site
state: Nova Scotia
city: Barrie
country: Canada
facility: 9.159.1393 Boehringer Ingelheim Investigational Site
state: Ontario
city: Hamilton
country: Canada
facility: 9.159.1395 Boehringer Ingelheim Investigational Site
state: Ontario
city: Kingston
country: Canada
facility: 9.159.1360 Boehringer Ingelheim Investigational Site
state: Ontario
city: London
country: Canada
facility: 9.159.1367 Boehringer Ingelheim Investigational Site
state: Ontario
city: London
country: Canada
facility: 9.159.1384 Boehringer Ingelheim Investigational Site
state: Ontario
city: Mississauga
country: Canada
facility: 9.159.1380 Boehringer Ingelheim Investigational Site
state: Ontario
city: Ottawa
country: Canada
facility: 9.159.1378 Boehringer Ingelheim Investigational Site
state: Ontario
city: Ottawa
country: Canada
facility: 9.159.1381 Ottawa Hospital General Campus
state: Ontario
city: Richmond Hill
country: Canada
facility: 9.159.1366 Boehringer Ingelheim Investigational Site
state: Ontario
city: Scarborough
country: Canada
facility: 9.159.1365 Boehringer Ingelheim Investigational Site
state: Ontario
city: Scarborough
country: Canada
facility: 9.159.1375 Boehringer Ingelheim Investigational Site
state: Ontario
city: Tecumseh
country: Canada
facility: 9.159.1391 Boehringer Ingelheim Investigational Site
state: Ontario
city: Thunder Bay
country: Canada
facility: 9.159.1369 Boehringer Ingelheim Investigational Site
state: Ontario
city: Toronto
country: Canada
facility: 9.159.1357 Boehringer Ingelheim Investigational Site
state: Ontario
city: Toronto
country: Canada
facility: 9.159.1379 Boehringer Ingelheim Investigational Site
state: Ontario
city: Toronto
country: Canada
facility: 9.159.1383 Boehringer Ingelheim Investigational Site
state: Ontario
city: Windsor
country: Canada
facility: 9.159.1363 Boehringer Ingelheim Investigational Site
state: Ontario
city: Greenfield Park
country: Canada
facility: 9.159.1359 Boehringer Ingelheim Investigational Site
state: Quebec
city: Montreal
country: Canada
facility: 9.159.1361 Boehringer Ingelheim Investigational Site
state: Quebec
city: Montreal
country: Canada
facility: 9.159.1362 Boehringer Ingelheim Investigational Site
state: Quebec
city: Montreal
country: Canada
facility: 9.159.1371 Boehringer Ingelheim Investigational Site
state: Quebec
city: Montreal
country: Canada
facility: 9.159.1374 Boehringer Ingelheim Investigational Site
state: Quebec
city: Montreal
country: Canada
facility: 9.159.1388 Boehringer Ingelheim Investigational Site
state: Quebec
city: Quebec City
country: Canada
facility: 9.159.1372 Boehringer Ingelheim Investigational Site
state: Quebec
city: Saguenay
country: Canada
facility: 9.159.1358 Boehringer Ingelheim Investigational Site
state: Quebec
city: St. Jerome
country: Canada
facility: 9.159.1364 Boehringer Ingelheim Investigational Site
state: Quebec
city: Regina
country: Canada
facility: 9.159.1389 Boehringer Ingelheim Investigational Site
state: Saskatchewan
city: Saskatoon
country: Canada
facility: 9.159.1396 Boehringer Ingelheim Investigational Site
state: Saskatchewan
city: Beijing
country: China
facility: 9.159.2490 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 9.159.2491 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 9.159.2492 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 9.159.2493 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 9.159.2494 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 9.159.2495 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 9.159.2496 Boehringer Ingelheim Investigational Site
city: Changchun, Jilin Province
country: China
facility: 9.159.2503 Boehringer Ingelheim Investigational Site
city: Changsha, Hunan Province
country: China
facility: 9.159.2500 Boehringer Ingelheim Investigational Site
city: Chengdu, Sichuan Province
country: China
facility: 9.159.2513 Boehringer Ingelheim Investigational Site
city: Chongqing
country: China
facility: 9.159.2512 Boehringer Ingelheim Investigational Site
city: Guangzhou, Guangdong Province
country: China
facility: 9.159.2507 Boehringer Ingelheim Investigational Site
city: Guangzhou, Guangdong Province
country: China
facility: 9.159.2510 Boehringer Ingelheim Investigational Site
city: Guangzhou
country: China
facility: 9.159.2509 Boehringer Ingelheim Investigational Site
city: Guangzhou
country: China
facility: 9.159.2518 Boehringer Ingelheim Investigational Site
city: Guangzhou
country: China
facility: 9.159.2521 Boehringer Ingelheim Investigational Site
city: Hangzhou, Zhejiang Province
country: China
facility: 9.159.2502 Boehringer Ingelheim Investigational Site
city: Harbin, Heilongjiang Province
country: China
facility: 9.159.2504 Boehringer Ingelheim Investigational Site
city: Jinan, Shandong Province
country: China
facility: 9.159.2505 Boehringer Ingelheim Investigational Site
city: Jinan, Shangdong Province
country: China
facility: 9.159.2506 Boehringer Ingelheim Investigational Site
city: Nanjing, Jiangsu Province
country: China
facility: 9.159.2517 Boehringer Ingelheim Investigational Site
city: Nanjing, Jiangsu Province
country: China
facility: 9.159.2519 Boehringer Ingelheim Investigational Site
city: Nanjing, Jiangsu Province
country: China
facility: 9.159.2520 Boehringer Ingelheim Investigational Site
city: Shanghai
country: China
facility: 9.159.2483 Boehringer Ingelheim Investigational Site
city: Shanghai
country: China
facility: 9.159.2484 Boehringer Ingelheim Investigational Site
city: Shanghai
country: China
facility: 9.159.2485 Boehringer Ingelheim Investigational Site
city: Shanghai
country: China
facility: 9.159.2486 Boehringer Ingelheim Investigational Site
city: Shanghai
country: China
facility: 9.159.2487 Boehringer Ingelheim Investigational Site
city: Shanghai
country: China
facility: 9.159.2488 Boehringer Ingelheim Investigational Site
city: Shanghai
country: China
facility: 9.159.2489 Boehringer Ingelheim Investigational Site
city: Suzhou, Jiangsu Province
country: China
facility: 9.159.2516 Boehringer Ingelheim Investigational Site
city: Tianjin
country: China
facility: 9.159.2497 Boehringer Ingelheim Investigational Site
city: Wenzhou, Zhejiang Province
country: China
facility: 9.159.2501 Boehringer Ingelheim Investigational Site
city: Wuhan, Hubei Province
country: China
facility: 9.159.2498 Boehringer Ingelheim Investigational Site
city: Wuhan, Hubei Province
country: China
facility: 9.159.2499 Boehringer Ingelheim Investigational Site
city: Xian, Shanxi Province
country: China
facility: 9.159.2515 Boehringer Ingelheim Investigational Site
city: Xian, Shanxi
country: China
facility: 9.159.2514 Boehringer Ingelheim Investigational Site
city: Xian
country: China
facility: 9.159.2511 Boehringer Ingelheim Investigational Site
city: Aarhuc C
country: Denmark
facility: 9.159.1636 Boehringer Ingelheim Investigational Site
city: Aarhus C
country: Denmark
facility: 9.159.1635 Boehringer Ingelheim Investigational Site
city: Esbjerg
country: Denmark
facility: 9.159.1639 Boehringer Ingelheim Investigational Site
city: Frederiksberg
country: Denmark
facility: 9.159.1634 Boehringer Ingelheim Investigational Site
city: Glostrup
country: Denmark
facility: 9.159.1637 Boehringer Ingelheim Investigational Site
city: Hellerup
country: Denmark
facility: 9.159.1640 Boehringer Ingelheim Investigational Site
city: Hvidovre
country: Denmark
facility: 9.159.1638 Boehringer Ingelheim Investigational Site
city: København NV
country: Denmark
facility: 9.159.1633 Boehringer Ingelheim Investigational Site
city: København Ø
country: Denmark
facility: 9.159.1631 Boehringer Ingelheim Investigational Site
city: Odense
country: Denmark
facility: 9.159.1632 Boehringer Ingelheim Investigational Site
city: Oviedo
country: El Salvador
facility: 9.159.2181 Boehringer Ingelheim Investigational Site
city: Helsinki
country: Finland
facility: 9.159.1655 Boehringer Ingelheim Investigational Site
city: Kuopio
country: Finland
facility: 9.159.1658 Boehringer Ingelheim Investigational Site
city: Lappeenranta
country: Finland
facility: 9.159.1659 Boehringer Ingelheim Investigational Site
city: Oulu
country: Finland
facility: 9.159.1656 Boehringer Ingelheim Investigational Site
city: Seinäjoki
country: Finland
facility: 9.159.1657 Boehringer Ingelheim Investigational Site
city: Lille cedex
country: France
facility: 9.159.1680 Boehringer Ingelheim Investigational Site
city: Limoges cedex 1
country: France
facility: 9.159.1683 Boehringer Ingelheim Investigational Site
city: Marseille cedex 05
country: France
facility: 9.159.1681 Boehringer Ingelheim Investigational Site
city: Nancy
country: France
facility: 9.159.1679 Boehringer Ingelheim Investigational Site
city: Paris cedex 19
country: France
facility: 9.159.1685 Boehringer Ingelheim Investigational Site
city: Poitiers cedex
country: France
facility: 9.159.1682 Boehringer Ingelheim Investigational Site
city: Tours cedex 9
country: France
facility: 9.159.1684 Boehringer Ingelheim Investigational Site
city: Bad Neustadt/Saale
country: Germany
facility: 9.159.1713 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 9.159.1736 Boehringer Ingelheim Investigational Site
city: Braunschweig
country: Germany
facility: 9.159.1732 Boehringer Ingelheim Investigational Site
city: Cloppenburg
country: Germany
facility: 9.159.1726 Boehringer Ingelheim Investigational Site
city: Dresden
country: Germany
facility: 9.159.1723 Boehringer Ingelheim Investigational Site
city: Düsseldorf
country: Germany
facility: 9.159.1728 Boehringer Ingelheim Investigational Site
city: Essen
country: Germany
facility: 9.159.1707 Boehringer Ingelheim Investigational Site
city: Freiburg
country: Germany
facility: 9.159.1738 Boehringer Ingelheim Investigational Site
city: Gießen
country: Germany
facility: 9.159.1720 Boehringer Ingelheim Investigational Site
city: Hamburg
country: Germany
facility: 9.159.1722 Boehringer Ingelheim Investigational Site
city: Hamburg
country: Germany
facility: 9.159.1739 Boehringer Ingelheim Investigational Site
city: Heidelberg
country: Germany
facility: 9.159.1724 Boehringer Ingelheim Investigational Site
city: Jena
country: Germany
facility: 9.159.1734 Boehringer Ingelheim Investigational Site
city: Kaiserslautern
country: Germany
facility: 9.159.1730 Boehringer Ingelheim Investigational Site
city: Köln
country: Germany
facility: 9.159.1737 Boehringer Ingelheim Investigational Site
city: Leipzig
country: Germany
facility: 9.159.1717 Boehringer Ingelheim Investigational Site
city: Ludwigshafen am Rhein
country: Germany
facility: 9.159.1735 Boehringer Ingelheim Investigational Site
city: Magdeburg
country: Germany
facility: 9.159.1712 Boehringer Ingelheim Investigational Site
city: Mainz
country: Germany
facility: 9.159.1710 Boehringer Ingelheim Investigational Site
city: Minden
country: Germany
facility: 9.159.1709 Boehringer Ingelheim Investigational Site
city: Mönchengladbach
country: Germany
facility: 9.159.1716 Boehringer Ingelheim Investigational Site
city: München
country: Germany
facility: 9.159.1718 Boehringer Ingelheim Investigational Site
city: München
country: Germany
facility: 9.159.1725 Boehringer Ingelheim Investigational Site
city: München
country: Germany
facility: 9.159.1729 Boehringer Ingelheim Investigational Site
city: Münster
country: Germany
facility: 9.159.1727 Boehringer Ingelheim Investigational Site
city: Nürnberg
country: Germany
facility: 9.159.1711 Boehringer Ingelheim Investigational Site
city: Regensburg
country: Germany
facility: 9.159.1719 Boehringer Ingelheim Investigational Site
city: Remscheid
country: Germany
facility: 9.159.1731 Boehringer Ingelheim Investigational Site
city: Rostock
country: Germany
facility: 9.159.1708 Boehringer Ingelheim Investigational Site
city: Saarbrücken
country: Germany
facility: 9.159.1715 Boehringer Ingelheim Investigational Site
city: Siegen
country: Germany
facility: 9.159.1714 Boehringer Ingelheim Investigational Site
city: Stuttgart
country: Germany
facility: 9.159.1733 Boehringer Ingelheim Investigational Site
city: Weimar
country: Germany
facility: 9.159.1721 Boehringer Ingelheim Investigational Site
city: Alexandroupolis
country: Greece
facility: 9.159.1826 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 9.159.1819 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 9.159.1820 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 9.159.1821 Boehringer Ingelheim Investigational Site
city: Ioannina
country: Greece
facility: 9.159.1825 Boehringer Ingelheim Investigational Site
city: Patras
country: Greece
facility: 9.159.1824 Boehringer Ingelheim Investigational Site
city: Hong KoNG
country: Hong Kong
facility: 9.159.2713 Boehringer Ingelheim Investigational Site
city: Hong Kong
country: Hong Kong
facility: 9.159.2714 Boehringer Ingelheim Investigational Site
city: Annamalainagar
country: India
facility: 9.159.2605 Boehringer Ingelheim Investigational Site
city: Bangalore
country: India
facility: 9.159.2603 Boehringer Ingelheim Investigational Site
city: Bangalore
country: India
facility: 9.159.2620 Boehringer Ingelheim Investigational Site
city: Bikaner
country: India
facility: 9.159.2616 Boehringer Ingelheim Investigational Site
city: Calicut
country: India
facility: 9.159.2618 Boehringer Ingelheim Investigational Site
city: Chennai
country: India
facility: 9.159.2604 Boehringer Ingelheim Investigational Site
city: Chennai
country: India
facility: 9.159.2619 Boehringer Ingelheim Investigational Site
city: Chennai
country: India
facility: 9.159.2625 Boehringer Ingelheim Investigational Site
city: Cochin
country: India
facility: 9.159.2606 Boehringer Ingelheim Investigational Site
city: Hyderabad
country: India
facility: 9.159.2607 Boehringer Ingelheim Investigational Site
city: Hyderabad
country: India
facility: 9.159.2624 Boehringer Ingelheim Investigational Site
city: Hyderabad
country: India
facility: 9.159.2630 Boehringer Ingelheim Investigational Site
city: Hyderabad
country: India
facility: 9.159.2632 Boehringer Ingelheim Investigational Site
city: Indore
country: India
facility: 9.159.2610 Boehringer Ingelheim Investigational Site
city: Jaipur
country: India
facility: 9.159.2615 Boehringer Ingelheim Investigational Site
city: Jaipur
country: India
facility: 9.159.2617 Boehringer Ingelheim Investigational Site
city: Jodhpur
country: India
facility: 9.159.2612 Boehringer Ingelheim Investigational Site
city: Kottayam
country: India
facility: 9.159.2621 Boehringer Ingelheim Investigational Site
city: Lucknow
country: India
facility: 9.159.2613 Boehringer Ingelheim Investigational Site
city: Ludhiana
country: India
facility: 9.159.2614 Boehringer Ingelheim Investigational Site
city: Mumbai
country: India
facility: 9.159.2611 Boehringer Ingelheim Investigational Site
city: New Delhi
country: India
facility: 9.159.2628 Boehringer Ingelheim Investigational Site
city: New Delhi
country: India
facility: 9.159.2629 Boehringer Ingelheim Investigational Site
city: Patiala
country: India
facility: 9.159.2623 Boehringer Ingelheim Investigational Site
city: Pune
country: India
facility: 9.159.2609 Boehringer Ingelheim Investigational Site
city: Pune
country: India
facility: 9.159.2622 Boehringer Ingelheim Investigational Site
city: Secunderabad
country: India
facility: 9.159.2627 Boehringer Ingelheim Investigational Site
city: Trichy
country: India
facility: 9.159.2626 Boehringer Ingelheim Investigational Site
city: Visakhapatnam
country: India
facility: 9.159.2631 Boehringer Ingelheim Investigational Site
city: Wardha
country: India
facility: 9.159.2608 Boehringer Ingelheim Investigational Site
city: Cork
country: Ireland
facility: 9.159.1851 Boehringer Ingelheim Investigational Site
city: Dublin 7
country: Ireland
facility: 9.159.1852 Boehringer Ingelheim Investigational Site
city: Ashkelon
country: Israel
facility: 9.159.2729 Barzilai Medical Center
city: Haifa
country: Israel
facility: 9.159.2721 Neurology Unit
city: Haifa
country: Israel
facility: 9.159.2724 Rambam Medical Center, Tel-Aviv Medical
city: Israel
country: Israel
facility: 9.159.2723 Boehringer Ingelheim Investigational Site
city: Naharia
country: Israel
facility: 9.159.2727 Western Galilee Hospital
city: Petach Tikva
country: Israel
facility: 9.159.2722 Neurology Unit
city: Tel Hashomer
country: Israel
facility: 9.159.2726 Sheba Medical Center
city: Tel-Aviv
country: Israel
facility: 9.159.2725 Tel Aviv Medical Center
city: Ancona
country: Italy
facility: 9.159.1875 Università degli Studi di Ancona
city: Cagliari
country: Italy
facility: 9.159.1882 Ospedale Brotzu
city: Como
country: Italy
facility: 9.159.1883 Azienda Ospedaliera S. Anna
city: Firenze
country: Italy
facility: 9.159.1871 Azienda Ospedaliera "Careggi"
city: Genova
country: Italy
facility: 9.159.1869 Università degli Studi di Genova
city: Jesi (ancona)
country: Italy
facility: 9.159.1870 ASL No. 5 di Jesi
city: L'aquila
country: Italy
facility: 9.159.1865 Ospedale Regionale "S. Salvatore"
city: Milano
country: Italy
facility: 9.159.1866 Ospedale S. Raffaele
city: Milano
country: Italy
facility: 9.159.1873 Istituto Scientifico "S. Luca"
city: Milano
country: Italy
facility: 9.159.1884 Ospedale S. Carlo Borromeo"
city: Napoli
country: Italy
facility: 9.159.1868 Ospedale "S. Maria di Loreto Mare"
city: Padova
country: Italy
facility: 9.159.1876 Azienda Ospedaliera di Padova -Policlinico Universitario
city: Palermo
country: Italy
facility: 9.159.1874 Ospedale Civico - ARNAS
city: Pozzilli (IS)
country: Italy
facility: 9.159.1872 Neuromed IRCCS
city: Roma
country: Italy
facility: 9.159.1879 Policlinico S. Andrea
city: Roma
country: Italy
facility: 9.159.1881 Università "La Sapienza"
city: Siracusa
country: Italy
facility: 9.159.1877 Azienda Ospedaliera Umberto I
city: Terni
country: Italy
facility: 9.159.1878 Azienda Ospedaliera "Santo Maria"
city: Torino
country: Italy
facility: 9.159.1864 Azienda Ospedaliera "S. Giovanni Battista"
city: Trieste
country: Italy
facility: 9.159.1863 Ospedale di Cattinara
city: Vibo Valentia
country: Italy
facility: 9.159.1867 Presidio Ospedaliero G.Jazzolino
city: Vicenza
country: Italy
facility: 9.159.1880 Ospedale Civile
city: Adachi-ku, Tokyo
country: Japan
facility: 9.159.2964 Boehringer Ingelheim Investigational Site
city: Akashi, Hyogo
country: Japan
facility: 9.159.2958 Boehringer Ingelheim Investigational Site
city: Akashi, Hyogo
country: Japan
facility: 9.159.2970 Boehringer Ingelheim Investigational Site
city: Ako, Hyogo
country: Japan
facility: 9.159.2965 Boehringer Ingelheim Investigational Site
city: Aoba-ku, Yokohama, Kanagawa
country: Japan
facility: 9.159.2968 Boehringer Ingelheim Investigational Site
city: Azumino, Nagano
country: Japan
facility: 9.159.2951 Boehringer Ingelheim Investigational Site
city: Chitose, Hokkaido
country: Japan
facility: 9.159.2959 Boehringer Ingelheim Investigational Site
city: Chuo-ku, Kobe, Hyogo
country: Japan
facility: 9.159.2944 Boehringer Ingelheim Investigational Site
city: Chuo-Ku, Sapporo, Hokkaido
country: Japan
facility: 9.159.2947 Boehringer Ingelheim Investigational Site
city: Fushimi-ku, Kyoto, Kyoto
country: Japan
facility: 9.159.2954 Boehringer Ingelheim Investigational Site
city: Habikino, Osaka
country: Japan
facility: 9.159.2942 Boehringer Ingelheim Investigational Site
city: Higashi-ku, Sapporo, Hokkaido
country: Japan
facility: 9.159.2948 Boehringer Ingelheim Investigational Site
city: Higashi-osaka, Osaka
country: Japan
facility: 9.159.2957 Boehringer Ingelheim Investigational Site
city: Higashinari-ku, Osaka, Osaka
country: Japan
facility: 9.159.2940 Boehringer Ingelheim Investigational Site
city: Higashiyodogawa-ku, Osaka, Osaka
country: Japan
facility: 9.159.2973 Boehringer Ingelheim Investigational Site
city: Hitachinaka, Ibaraki
country: Japan
facility: 9.159.2949 Boehringer Ingelheim Investigational Site
city: Iida, Nagano
country: Japan
facility: 9.159.2953 Boehringer Ingelheim Investigational Site
city: Izumisano, Osaka
country: Japan
facility: 9.159.2943 Boehringer Ingelheim Investigational Site
city: Jyonan-ku, Fukuoka, Fukuoka
country: Japan
facility: 9.159.2963 Boehringer Ingelheim Investigational Site
city: Kasama, Ibaraki
country: Japan
facility: 9.159.2933 Boehringer Ingelheim Investigational Site
city: Kasuga, Fukuoka
country: Japan
facility: 9.159.2955 Boehringer Ingelheim Investigational Site
city: Kita-ku, Osaka, Osaka
country: Japan
facility: 9.159.2938 Boehringer Ingelheim Investigational Site
city: Koriyama, Fukushima
country: Japan
facility: 9.159.2967 Boehringer Ingelheim Investigational Site
city: Kushiro, Hokkaido
country: Japan
facility: 9.159.2969 Boehringer Ingelheim Investigational Site
city: Matsumoto, Nagano
country: Japan
facility: 9.159.2952 Boehringer Ingelheim Investigational Site
city: Midori-ku, Yokohama, Kanagawa
country: Japan
facility: 9.159.2961 Boehringer Ingelheim Investigational Site
city: Moriya, Ibaraki
country: Japan
facility: 9.159.2934 Boehringer Ingelheim Investigational Site
city: Musashino, Tokyo
country: Japan
facility: 9.159.2971 Boehringer Ingelheim Investigational Site
city: Nakagawa-ku, Nagoya, Aichi
country: Japan
facility: 9.159.2962 Boehringer Ingelheim Investigational Site
city: Nishi-yodogawa-ku, Osaka, Osaka
country: Japan
facility: 9.159.2939 Boehringer Ingelheim Investigational Site
city: Ohnojo, Fukuoka
country: Japan
facility: 9.159.2956 Boehringer Ingelheim Investigational Site
city: Sakai-ku, Sakai, Osaka
country: Japan
facility: 9.159.2941 Boehringer Ingelheim Investigational Site
city: Sawara-ku, Fukuoka, Fukuoka
country: Japan
facility: 9.159.2945 Boehringer Ingelheim Investigational Site
city: Shimogyo-ku, Kyoto, Kyoto
country: Japan
facility: 9.159.2937 Boehringer Ingelheim Investigational Site
city: Shiroishi, Miyagi
country: Japan
facility: 9.159.2966 Boehringer Ingelheim Investigational Site
city: Suwa, Nagano
country: Japan
facility: 9.159.2936 Boehringer Ingelheim Investigational Site
city: Takikawa, Hokkaido
country: Japan
facility: 9.159.2946 Boehringer Ingelheim Investigational Site
city: Tatebayashi, Gunma
country: Japan
facility: 9.159.2935 Boehringer Ingelheim Investigational Site
city: Tsuchiura, Ibaraki
country: Japan
facility: 9.159.2950 Boehringer Ingelheim Investigational Site
city: Yao, Osaka
country: Japan
facility: 9.159.2972 Boehringer Ingelheim Investigational Site
city: Gwangju
country: Korea, Republic of
facility: 9.159.1593 Boehringer Ingelheim Investigational Site
city: Incheon
country: Korea, Republic of
facility: 9.159.1595 Boehringer Ingelheim Investigational Site
city: Kyunggi-do
country: Korea, Republic of
facility: 9.159.1592 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 9.159.1591 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 9.159.1594 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 9.159.1597 Boehringer Ingelheim Investigational Site
city: Suwon
country: Korea, Republic of
facility: 9.159.1596 Boehringer Ingelheim Investigational Site
city: Kelantan Darul Naim
country: Malaysia
facility: 9.159.2707 Boehringer Ingelheim Investigational Site
city: Kuala Lumpur
country: Malaysia
facility: 9.159.2706 Boehringer Ingelheim Investigational Site
city: Metepec
country: Mexico
facility: 9.159.2765 Boehringer Ingelheim Investigational Site
city: 's-Hertogenbosch
country: Netherlands
facility: 9.159.1960 Jeroen Bosch Ziekenhuis
city: Alkmaar
country: Netherlands
facility: 9.159.1945 Medisch Centrum Alkmaar
city: Assen
country: Netherlands
facility: 9.159.1963 Polikliniek Neurologie
city: Blaricum
country: Netherlands
facility: 9.159.1949 Ziekenhuis Gooi-Noord
city: Breda
country: Netherlands
facility: 9.159.1962 Locatie Molengracht
city: Den Haag
country: Netherlands
facility: 9.159.1950 HagaZiekenhuis
city: Eindhoven
country: Netherlands
facility: 9.159.1959 Catharina Ziekenhuis
city: Emmen
country: Netherlands
facility: 9.159.1946 Scheper Ziekenhuis
city: Enschede
country: Netherlands
facility: 9.159.1958 Medisch Spectrum Twente
city: Groningen
country: Netherlands
facility: 9.159.1943 Umcg
city: Groningen
country: Netherlands
facility: 9.159.1961 Lokatie Van Swieten
city: Heerlen
country: Netherlands
facility: 9.159.1953 Atrium Medisch Centrum
city: Helmond
country: Netherlands
facility: 9.159.1955 Elkerliek Ziekenhuis
city: Hengelo
country: Netherlands
facility: 9.159.1951 Ziekenhuisgroep Twente
city: Leeuwarden
country: Netherlands
facility: 9.159.1948 Medisch Centrum Leeuwarden
city: Leiderdorp
country: Netherlands
facility: 9.159.1952 Rijnland Ziekenhuis
city: Nieuwegein
country: Netherlands
facility: 9.159.1947 Sint Antonius Ziekenhuis
city: Nijmegen
country: Netherlands
facility: 9.159.1964 Canisius-Wilhelmina ziekenhuis
city: Tilburg
country: Netherlands
facility: 9.159.1956 TweeSteden Ziekenhuis Tilburg
city: Tilburg
country: Netherlands
facility: 9.159.1957 Sint Elisabeth Ziekenhuis
city: Veldhoven
country: Netherlands
facility: 9.159.1944 Máxima Medisch Centrum
city: Weert
country: Netherlands
facility: 9.159.1954 St. Jans Gasthuis
city: Bergen
country: Norway
facility: 9.159.2029 Boehringer Ingelheim Investigational Site
city: Oslo
country: Norway
facility: 9.159.2028 Boehringer Ingelheim Investigational Site
city: Trondheim
country: Norway
facility: 9.159.2027 Boehringer Ingelheim Investigational Site
city: Amadora
country: Portugal
facility: 9.159.2040 Hospital Fernando Fonseca
city: Coimbra
country: Portugal
facility: 9.159.2039 Centro Hospitalar e Universitário de Coimbra, EPE
city: Lisboa
country: Portugal
facility: 9.159.2041 Centro Hospitalar de Lisboa Norte
city: Porto
country: Portugal
facility: 9.159.2042 Centro Hospitalar do Porto
city: Ekaterinburg
country: Russian Federation
facility: 9.159.2114 Boehringer Ingelheim Investigational Site
city: Kazan
country: Russian Federation
facility: 9.159.2102 Boehringer Ingelheim Investigational Site
city: Kemerovo
country: Russian Federation
facility: 9.159.2117 Boehringer Ingelheim Investigational Site
city: Kirov
country: Russian Federation
facility: 9.159.2107 Boehringer Ingelheim Investigational Site
city: Krasnoyarsk
country: Russian Federation
facility: 9.159.2116 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2079 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2080 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2081 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2082 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2083 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2084 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2085 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2087 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2088 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2089 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2090 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2091 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2092 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2093 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2095 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2098 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 9.159.2101 Boehringer Ingelheim Investigational Site
city: Nizhnyi Novgorod
country: Russian Federation
facility: 9.159.2105 Boehringer Ingelheim Investigational Site
city: Novosibirsk
country: Russian Federation
facility: 9.159.2115 Boehringer Ingelheim Investigational Site
city: Omsk
country: Russian Federation
facility: 9.159.2119 Boehringer Ingelheim Investigational Site
city: Orel
country: Russian Federation
facility: 9.159.2111 Boehringer Ingelheim Investigational Site
city: Rostov-na-Donu
country: Russian Federation
facility: 9.159.2106 Boehringer Ingelheim Investigational Site
city: Samara
country: Russian Federation
facility: 9.159.2108 Boehringer Ingelheim Investigational Site
city: Saratov
country: Russian Federation
facility: 9.159.2109 Boehringer Ingelheim Investigational Site
city: Saratov
country: Russian Federation
facility: 9.159.2110 Boehringer Ingelheim Investigational Site
city: Seversk
country: Russian Federation
facility: 9.159.2118 Boehringer Ingelheim Investigational Site
city: Smolensk
country: Russian Federation
facility: 9.159.2086 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 9.159.2094 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 9.159.2097 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 9.159.2099 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 9.159.2100 Boehringer Ingelheim Investigational Site
city: Ufa
country: Russian Federation
facility: 9.159.2120 Boehringer Ingelheim Investigational Site
city: Volgograd
country: Russian Federation
facility: 9.159.2112 Boehringer Ingelheim Investigational Site
city: Volgograd
country: Russian Federation
facility: 9.159.2113 Boehringer Ingelheim Investigational Site
city: Voronezh
country: Russian Federation
facility: 9.159.2104 Boehringer Ingelheim Investigational Site
city: Yaroslavl
country: Russian Federation
facility: 9.159.2103 Boehringer Ingelheim Investigational Site
city: Singapore
country: Singapore
facility: 9.159.2703 Boehringer Ingelheim Investigational Site
city: Singapore
country: Singapore
facility: 9.159.2704 Boehringer Ingelheim Investigational Site
city: Singapore
country: Singapore
facility: 9.159.2705 Boehringer Ingelheim Investigational Site
city: Bloemfontein
country: South Africa
facility: 9.159.2060 Boehringer Ingelheim Investigational Site
city: Cape Town
country: South Africa
facility: 9.159.2056 Boehringer Ingelheim Investigational Site
city: Durban
country: South Africa
facility: 9.159.2057 Boehringer Ingelheim Investigational Site
city: Johannesburg
country: South Africa
facility: 9.159.2055 Boehringer Ingelheim Investigational Site
city: Johannesburg
country: South Africa
facility: 9.159.2061 Boehringer Ingelheim Investigational Site
city: Pretoria
country: South Africa
facility: 9.159.2058 Boehringer Ingelheim Investigational Site
city: Sunninghill
country: South Africa
facility: 9.159.2059 Boehringer Ingelheim Investigational Site
city: Alicante
country: Spain
facility: 9.159.2179 Boehringer Ingelheim Investigational Site
city: Barcelona
country: Spain
facility: 9.159.2177 Boehringer Ingelheim Investigational Site
city: Hospitalet de Llobregat (Barcelona)
country: Spain
facility: 9.159.2178 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 9.159.2175 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 9.159.2176 Boehringer Ingelheim Investigational Site
city: Pamplona
country: Spain
facility: 9.159.2180 Boehringer Ingelheim Investigational Site
city: Borås
country: Sweden
facility: 9.159.2223 Boehringer Ingelheim Investigational Site
city: Eskilstuna
country: Sweden
facility: 9.159.2209 Boehringer Ingelheim Investigational Site
city: Göteborg
country: Sweden
facility: 9.159.2204 Boehringer Ingelheim Investigational Site
city: Göteborg
country: Sweden
facility: 9.159.2205 Boehringer Ingelheim Investigational Site
city: Holon
country: Sweden
facility: 9.159.2728 Neurology Unit
city: Jönköping
country: Sweden
facility: 9.159.2210 Boehringer Ingelheim Investigational Site
city: Lund
country: Sweden
facility: 9.159.2206 Boehringer Ingelheim Investigational Site
city: Mora
country: Sweden
facility: 9.159.2211 Boehringer Ingelheim Investigational Site
city: Skellefteå
country: Sweden
facility: 9.159.2216 Boehringer Ingelheim Investigational Site
city: Skövde
country: Sweden
facility: 9.159.2215 Boehringer Ingelheim Investigational Site
city: Stockholm
country: Sweden
facility: 9.159.2203 Boehringer Ingelheim Investigational Site
city: Stockholm
country: Sweden
facility: 9.159.2212 Boehringer Ingelheim Investigational Site
city: Stockholm
country: Sweden
facility: 9.159.2213 Boehringer Ingelheim Investigational Site
city: Stockholm
country: Sweden
facility: 9.159.2222 Boehringer Ingelheim Investigational Site
city: Stockholm
country: Sweden
facility: 9.159.2225 Boehringer Ingelheim Investigational Site
city: Umeå
country: Sweden
facility: 9.159.2207 Boehringer Ingelheim Investigational Site
city: Värnamo
country: Sweden
facility: 9.159.2214 Boehringer Ingelheim Investigational Site
city: Västervik
country: Sweden
facility: 9.159.2224 Boehringer Ingelheim Investigational Site
city: Örebro
country: Sweden
facility: 9.159.2208 Boehringer Ingelheim Investigational Site
city: Kaohsiung
country: Taiwan
facility: 9.159.2250 Boehringer Ingelheim Investigational Site
city: Kaohsiung
country: Taiwan
facility: 9.159.2253 Boehringer Ingelheim Investigational Site
city: Taichung
country: Taiwan
facility: 9.159.2248 Boehringer Ingelheim Investigational Site
city: Taichung
country: Taiwan
facility: 9.159.2249 Boehringer Ingelheim Investigational Site
city: Tainan
country: Taiwan
facility: 9.159.2251 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 9.159.2244 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 9.159.2245 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 9.159.2246 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 9.159.2247 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 9.159.2252 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 9.159.2254 Boehringer Ingelheim Investigational Site
city: Taoyuan
country: Taiwan
facility: 9.159.2243 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 9.159.2797 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 9.159.2798 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 9.159.2799 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 9.159.2800 Boehringer Ingelheim Investigational Site
city: Chiang Mai
country: Thailand
facility: 9.159.2801 Boehringer Ingelheim Investigational Site
city: Ankara
country: Turkey
facility: 9.159.2830 Boehringer Ingelheim Investigational Site
city: Antalya
country: Turkey
facility: 9.159.2829 Boehringer Ingelheim Investigational Site
city: Bursa
country: Turkey
facility: 9.159.2831 Boehringer Ingelheim Investigational Site
city: Eskisehir
country: Turkey
facility: 9.159.2827 Boehringer Ingelheim Investigational Site
city: Istanbul
country: Turkey
facility: 9.159.2825 Boehringer Ingelheim Investigational Site
city: Istanbul
country: Turkey
facility: 9.159.2826 Boehringer Ingelheim Investigational Site
city: Izmir
country: Turkey
facility: 9.159.2828 Dkuz Eylul Universitesi Tip Fakultesi Noroloji A.B.D.
city: Dnepropetrovsk
country: Ukraine
facility: 9.159.2387 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 9.159.2384 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 9.159.2385 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 9.159.2386 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 9.159.2392 Boehringer Ingelheim Investigational Site
city: Kyiv
country: Ukraine
facility: 9.159.2379 Boehringer Ingelheim Investigational Site
city: Kyiv
country: Ukraine
facility: 9.159.2380 Boehringer Ingelheim Investigational Site
city: Kyiv
country: Ukraine
facility: 9.159.2382 Boehringer Ingelheim Investigational Site
city: Odesa
country: Ukraine
facility: 9.159.2389 Boehringer Ingelheim Investigational Site
city: Odesa
country: Ukraine
facility: 9.159.2390 Boehringer Ingelheim Investigational Site
city: Vinnytzya
country: Ukraine
facility: 9.159.2391 Boehringer Ingelheim Investigational Site
city: Zaporizhzhya
country: Ukraine
facility: 9.159.2388 Boehringer Ingelheim Investigational Site
city: Belfast
country: United Kingdom
facility: 9.159.2304 Boehringer Ingelheim Investigational Site
city: Birmingham
country: United Kingdom
facility: 9.159.2297 Boehringer Ingelheim Investigational Site
city: Bournemouth
country: United Kingdom
facility: 9.159.2299 Boehringer Ingelheim Investigational Site
city: Bristol
country: United Kingdom
facility: 9.159.2301 Boehringer Ingelheim Investigational Site
city: Dundee
country: United Kingdom
facility: 9.159.2298 Boehringer Ingelheim Investigational Site
city: Exeter
country: United Kingdom
facility: 9.159.2307 Boehringer Ingelheim Investigational Site
city: Glasgow
country: United Kingdom
facility: 9.159.2296 Boehringer Ingelheim Investigational Site
city: Glasgow
country: United Kingdom
facility: 9.159.2300 Boehringer Ingelheim Investigational Site
city: Harrow
country: United Kingdom
facility: 9.159.2287 Boehringer Ingelheim Investigational Site
city: Henshingham, Whitehaven
country: United Kingdom
facility: 9.159.2303 Boehringer Ingelheim Investigational Site
city: Leicester
country: United Kingdom
facility: 9.159.2308 Boehringer Ingelheim Investigational Site
city: Liverpool
country: United Kingdom
facility: 9.159.2295 Boehringer Ingelheim Investigational Site
city: London
country: United Kingdom
facility: 9.159.2286 Boehringer Ingelheim Investigational Site
city: London
country: United Kingdom
facility: 9.159.2293 Boehringer Ingelheim Investigational Site
city: London
country: United Kingdom
facility: 9.159.2294 Boehringer Ingelheim Investigational Site
city: Mansfield
country: United Kingdom
facility: 9.159.2305 Boehringer Ingelheim Investigational Site
city: Newcastle Upon Tyne
country: United Kingdom
facility: 9.159.2290 Boehringer Ingelheim Investigational Site
city: North Shields
country: United Kingdom
facility: 9.159.2288 Boehringer Ingelheim Investigational Site
city: Northampton
country: United Kingdom
facility: 9.159.2285 Boehringer Ingelheim Investigational Site
city: Nottingham
country: United Kingdom
facility: 9.159.2284 Boehringer Ingelheim Investigational Site
city: Poole
country: United Kingdom
facility: 9.159.2283 Boehringer Ingelheim Investigational Site
city: Rotherham
country: United Kingdom
facility: 9.159.2302 Boehringer Ingelheim Investigational Site
city: Sheffield
country: United Kingdom
facility: 9.159.2292 Boehringer Ingelheim Investigational Site
city: Southampton
country: United Kingdom
facility: 9.159.2289 Boehringer Ingelheim Investigational Site
city: Stoke on Trent
country: United Kingdom
facility: 9.159.2306 Boehringer Ingelheim Investigational Site
city: Sunderland
country: United Kingdom
facility: 9.159.2291 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References:
citation: Ovbiagele B, Bath PM, Cotton D, Sha N, Diener HC; PRoFESS Investigators. Low glomerular filtration rate, recurrent stroke risk, and effect of renin-angiotensin system modulation. Stroke. 2013 Nov;44(11):3223-5. doi: 10.1161/STROKEAHA.113.002463. Epub 2013 Aug 29.
citation: Bohm M, Cotton D, Foster L, Custodis F, Laufs U, Sacco R, Bath PM, Yusuf S, Diener HC. Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. Eur Heart J. 2012 Nov;33(22):2804-12. doi: 10.1093/eurheartj/ehs250. Epub 2012 Aug 26.
citation: Weber R, Weimar C, Blatchford J, Hermansson K, Wanke I, Moller-Hartmann C, Gizewski ER, Forsting M, Demchuk AM, Sacco RL, Saver JL, Warach S, Diener HC, Diehl A; PRoFESS Imaging Substudy Group. Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy. Stroke. 2012 Sep;43(9):2336-42. doi: 10.1161/STROKEAHA.111.648576. Epub 2012 Jun 26.
citation: Weber R, Weimar C, Wanke I, Moller-Hartmann C, Gizewski ER, Blatchford J, Hermansson K, Demchuk AM, Forsting M, Sacco RL, Saver JL, Warach S, Diener HC, Diehl A; PRoFESS Imaging Substudy Group. Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy. Stroke. 2012 Feb;43(2):350-5. doi: 10.1161/STROKEAHA.111.631739. Epub 2012 Jan 19.
citation: Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, Donnan GA, Bath PM; PROFESS Investigators. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA. 2011 Nov 16;306(19):2137-44. doi: 10.1001/jama.2011.1650.
citation: Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008 Oct;7(10):875-84. doi: 10.1016/S1474-4422(08)70198-4. Epub 2008 Aug 29.
citation: Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008 Sep 18;359(12):1225-37. doi: 10.1056/NEJMoa0804593. Epub 2008 Aug 27.
citation: Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008 Sep 18;359(12):1238-51. doi: 10.1056/NEJMoa0805002. Epub 2008 Aug 27.